The combination of anti-CTLA-4 and anti-PD-(L)1 therapy is because that they affect T cell activation through different mechanisms, affecting different subsets of TILs at different stages and in different regions, so that they play more effective anti-tumor effects. This evidence concerns the gene CTLA4 and neoplasm.